Abstract
Fexofenadine, the active metabolite of terfenadine, a well known and effective H1 receptor antagonist, is administered by the oral route. The objective of present investigation was to develop and characterize a liquid self-emulsifying drug delivery system (SEDDS) and a solid SEDDS by using bioenhancer excipients like Tween 80 and Labrasol which are known for their inhibiting action on CYP450 and P-glycoprotein pump. Solubility of fexofenadine was determined in various vehicles, including oils, surfactants and co-solvents. Various evaluation parameters (emulsification study, particle size, poly-dispersibility index, % drug release, etc.) were carried out to find out optimized liquid SEDDS formulation. Optimized liquid formulations were converted in solid SEDDS by simple and convenient physical adsorption technique. Solid SEDDS was characterized by X-ray diffraction (XRD), differential scanning calorimetry (DSC), scanning electron microscopy (SEM) and Fourier transport infra-red spectroscopy. The optimized liquid SEDDS formulation contained 29 % Captex 200P/Capmul MCM C8 EP as oil, 47 % Labrasol/Tween 80 as a surfactant and 24 % Ethanol as a co-solvent. The optimized liquid and solid SEDDS showed higher drug release than pure API powder. DSC and XRD results of solid SEDDS confirmed that the drug presented in the formulation was in an amorphous state. The prepared liquid SEDDS and solid SEDDS containing bio-enhancer excipients increased the in vitro dissolution rate of fexofenadine compared to pure drug and has potential to increase bioavailability by blocking Pgp efflux pump and CYP450 hepatic metabolism.
Similar content being viewed by others
References
Balakrishnan P, Lee BJ, Oh DH, Kim JO, Hong MJ, Jee JP, Choi HG (2009) Enhanced oral bioavailability of dexibuprofen by a novel solid Self-emulsifying drug delivery system (SEDDS). Eur J Pharm Biopharm 72:539–545. doi:10.1016/j.ejpb.2009.03.001
Chakraborty S, Shukla D, Mishra B, Singh S (2009) Lipid: an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm 73:1–15. doi:10.1016/j.ejpb.2009.06.001
Charman WN (1992) Lipid vehicle and formulation effects on intestinal lymphatic drug transport. Lymphatic transport of drugs. CRC Press, Boca Raton, pp 113–179
Cornaire G, Woodley J, Hermann P, Cloarec A, Arellano C, Houin G (2004) Impact of excipients on the absorption of P-glycoprotein substrates in vitro and in vivo. Int J Pharm 278:119–131. doi:10.1016/j.ijpharm.2004.03.001
Date AA, Nagarsenker MS (2007) Design and evaluation of self-nanoemulsifying drug delivery systems (SNEDDS) for cefpodoxime proxetil. Int J Pharm 329:166–172. doi:10.1016/j.ijpharm.2006.08.038
Drescher S, Schaeffeler E, Hitzl M, Hofmann U, Schwab M, Brinkmann U, Fromm MF (2002) MDR1 gene polymorphisms and disposition of the P-glycoprotein substrate fexofenadine. Brit J Clin Pharmacol 53:526–534. doi:10.1046/j.1365-2125.2002.01591.x
Gershanik T, Benita S (2000) Self-dispersing lipid formulations for improving oral absorption of lipophilic drugs. Eur J Pharm Biopharm 50:179–188
Jahan ST, Khan SR, Moniruzzaman M, Rahman MR, Sadat MA, Jalil RU (2011) Enhancement of dissolution profile for oral delivery of fexofenadine Hydrochloride by solid dispersion (solvent evaporation) technique. Am J Sci Ind Res 2:112–115
Nazzal S, Smalyukh II, Lavrentovich OD, Khan MA (2002) Preparation and in vitro characterization of a eutectic based semisolid self-nanoemulsified drug delivery system (SNEDDS) of ubiquinone: mechanism and progress of emulsion formation. Int J Pharm 235:247–265. doi:10.1016/S0378-5173(02)00003-0
Neslihan GR, Benita S (2004) Self-emulsifying drug delivery systems (SEDDS) for improved oral delivery of lipophilic drugs. Biomed Pharmacother 58:173–182. doi:10.1016/j.biopha.2004.02.001
Pandya SJ, Pasha TY, Bhandari A, Patel JK, Naitik T, Upama T (2011) Physical characterization and enhance the solubility of fexofenadine-β-cyclodextrin inclusion complexes. CPR 1:260–266
Patel HK, Patel PV, Misan CK, Mehta DS, Patel MB (2012) Development and characterization of liquid and solid self-microemulsifying drug delivery system of Tacrolimus. Asian J Pharm 6:204–209
Piao HM, Balakrishnan P, Cho HJ, Kim H, Kim YS, Chung SJ, Kim DD (2010) Preparation and evaluation of fexofenadine microemulsions for intranasal delivery. Int J Pharm 395:309–316. doi:10.1016/j.ijpharm.2010.05.041
Pouton CW, Porter CJ (2008) Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deli Rev 60:625–637. doi:10.1016/j.addr.2007.10.010
Rege BD, Kao JP, Polli JE (2002) Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers. Eur J Pharm Sci 16:237–246. doi:10.1016/S0928-0987(02)00055-6
Shimizu M, Uno T, Sugawara K, Tateishi T (2006) Effects of itraconazole and diltiazem on the pharmacokinetics of fexofenadine, a substrate of P-glycoprotein. Brit J Clin Pharmacol 61:538–544. doi:10.1111/j.1365-2125.2006.02613.x
Tang B, Cheng G, Gu JC, Xu CH (2008) Development of solid self-emulsifying drug delivery systems: preparation techniques and dosage forms. Drug Discov Today 13:606–612. doi:10.1016/j.drudis.2008.04.006
Wandel C, Kim RB, Stein CM (2003) “Inactive” excipients such as Cremophor can affect in vivo drug disposition. Clin Pharmacol Ther 73:394–396
Wang Z, Sun J, Wang Y, Liu X, Liu Y, Fu Q, He Z (2010) Solid self-emulsifying nitrendipine pellets: Preparation and in vitro in vivo evaluation. Int J Pharm 383:1–6. doi:10.1016/j.ijpharm.2009.08.014
Acknowledgments
The Authors are grateful for financial support provided from the A. K. Raval Charitable Trust. We are thankful to Gateefosse, India for providing the gift samples of Maisin 35-1 and Labrasol. We are also thankful to ABITEC, Mumbai, India for providing the gift samples Capmul MCM and Captex 200P.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Trivedi, K., Patel, P.V. & Pujara, Z. Development and characterization of liquid and solid self-emulsifying drug delivery system of fexofenadine. Journal of Pharmaceutical Investigation 43, 385–394 (2013). https://doi.org/10.1007/s40005-013-0083-2
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40005-013-0083-2